Jul 5, 2022

Biomica to Present at the Microbiome Connect Europe 2022

Rehovot, Israel – July 5, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced it will be presenting at Microbiome Connect Europe taking place between July 6-7, 2022,  in Amsterdam, Netherlands.

The Annual Microbiome Connect Europe is dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers.

In attendance will be Dr. Shiri Meshner, VP R&D at Biomica, who will be presenting both on behalf of the Company and as part of a panel at the conference.

On July 6, 2022, Dr. Meshner will be part of a panel entitled, Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy, which is scheduled for 11:30am CET.

On July 7, 2022, at 3:45pm CET, Dr. Meshner will be providing an overview and recent updates on Biomica’s BMC128 in a talk entitled, BMC128 – A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors.

Dr. Meshner will also be available for one-on-one meetings at the conference, and those interested should be in touch with the investor or public relations team.

 

About Biomica

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN). For more information, please visit www.biomicamed.com.

 

 

Contacts

Lital Mamon

Head of Marketing and PR

E: IR@evogene.com

T: +972-8-931-2097

 

Kenny Green

US Investor Relations

E: IR@evogene.com

T: +1 212 378 8040

Back to all News

Highlighted News About Biomica

ASCO 2024 logo
Apr 16, 2024

American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

We’re pleased to announce that Dr. Shiri Meshner, our VP of Research and Development, will be participating in the Pharmabiotic Conference 2024. She’ll be presenting alongside Claire Derlot, Chief Business Officer of Biose Industrie, on the topic “Biomica & Biose Industrie: The clinical journey of a multi-strain LBP”. Additionally, Dr. Meshner will contribute to a panel discussion focusing on Clinical Design & Methodology.